These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 10652560

  • 1. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
    Sinha AA, Quast BJ, Korkowski JC, Wilson MJ, Reddy PK, Ewing SL, Sloane BF, Gleason DF.
    Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
    Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Sloane BF, Gleason DF.
    Prostate; 2001 Sep 15; 48(4):274-84. PubMed ID: 11536307
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization.
    Sinha AA, Gleason DF, Deleon OF, Wilson MJ, Sloane BF.
    Anat Rec; 1993 Feb 15; 235(2):233-40. PubMed ID: 7678371
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL.
    Cancer; 2007 Jan 15; 109(2):198-204. PubMed ID: 17171704
    [Abstract] [Full Text] [Related]

  • 10. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS.
    Cancer Res; 2000 Dec 15; 60(24):7099-105. PubMed ID: 11156417
    [Abstract] [Full Text] [Related]

  • 11. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
    Kehinde EO, Maghrebi MA, Anim JT.
    Can J Urol; 2008 Apr 15; 15(2):3967-74. PubMed ID: 18405443
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
    Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brünner N.
    Clin Cancer Res; 2000 Feb 15; 6(2):505-11. PubMed ID: 10690531
    [Abstract] [Full Text] [Related]

  • 17. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
    Sinha AA, Quast BJ, Reddy PK, Lall V, Wilson MJ, Qian J, Bostwick DG.
    Exp Mol Pathol; 2004 Oct 15; 77(2):153-9. PubMed ID: 15351240
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, Smith JA, Shappell SB.
    J Urol; 2002 Aug 15; 168(2):519-24. PubMed ID: 12131301
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.